This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Top Research Reports for Tesla, UnitedHealth & Shopify
by Mark Vickery
Tesla grapples with delivery declines and margin pressure but eyes its robotaxi launch and energy unit as potential growth engines.
CCLPositive Net Change UNHNegative Net Change ETRNegative Net Change TSLAPositive Net Change LNGNegative Net Change SHOPNegative Net Change WSBFNegative Net Change
auto-tires-trucks computers finance medical
Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
by Zacks Equity Research
AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.
PFEPositive Net Change AMGNPositive Net Change GDRXNegative Net Change
biotechs medical pharmaceuticals
UnitedHealth Jumps 12% in a Month: But is it Healthy Enough to Buy?
by Kaibalya Pravo Dey
UNH surges 12% in a month, but with rising costs and regulatory pressures, is now the time to buy or wait?
UNHNegative Net Change BRK.BNegative Net Change HUMNegative Net Change ELVNegative Net Change
healthcare hmo insurance medical
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
by Zacks Equity Research
NYXH's first U.S. commercial use of its Genio system signals strong physician demand and sets the stage for broad adoption in sleep apnea care.
WSTPositive Net Change MEDPPositive Net Change NVSTNegative Net Change NYXHPositive Net Change
medical medical-devices
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
by Zacks Equity Research
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
NVONegative Net Change FOLDPositive Net Change AVDLPositive Net Change SKYEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
by Ahan Chakraborty
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
PFEPositive Net Change AMPHPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
by Zacks Equity Research
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
GSKNegative Net Change MRKNegative Net Change GILDPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Do Options Traders Know Something About Alkermes Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ALKS stock based on the movements in the options market lately.
ALKSNegative Net Change
medical
Zacks.com featured highlights include Maximus, Pediatrix Medical, Sally Beauty and State Street
by Santanu Roy
Zacks highlights Maximus, Pediatrix Medical, Sally Beauty, and State Street as stocks trading near 52-week highs with potential for continued upside.
STTNegative Net Change SBHPositive Net Change MDNegative Net Change MMSNegative Net Change
business-services finance medical retail
Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock
by Zacks Equity Research
TMO joins AstraZeneca's BioVentureHub to boost R&D, innovation and life science access.
AZNNegative Net Change TMOPositive Net Change MASINegative Net Change PAHCPositive Net Change
medical medical-devices
Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics
by Zacks Equity Research
Zacks highlights Amicus Therapeutics, Micron Technology, and General Dynamics as top picks with upgraded broker ratings and strong earnings outlooks.
GDNegative Net Change MUNegative Net Change FOLDPositive Net Change
aerospace computers medical
Reasons to Add Omnicell Stock to Your Portfolio Right Now
by Zacks Equity Research
OMCL's expanding SaaS portfolio, overseas growth plans, and solid balance sheet position it for sustained momentum despite rising competition.
BSXPositive Net Change OMCLNegative Net Change MASINegative Net Change PAHCPositive Net Change
medical
CAH Expands Distribution Network With Indianapolis Facility
by Zacks Equity Research
Cardinal Health accelerates its multi-year supply chain transformation with a new flagship Indianapolis distribution center, reinforcing automation-driven efficiency while building on recent logistics expansions in Ohio and Texas.
CAHPositive Net Change MASINegative Net Change MMSIPositive Net Change WSTPositive Net Change
medical medical-devices
New Strong Buy Stocks for October 7th
by Zacks Equity Research
ALHC, STNE, EGAN, PAHC and MTG have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2025.
MTGNegative Net Change EGANPositive Net Change PAHCPositive Net Change STNEPositive Net Change ALHCNegative Net Change
insurance medical
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
by Zacks Equity Research
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
AZNNegative Net Change PFEPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
by Zacks Equity Research
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
RHHBYNegative Net Change JAZZPositive Net Change ETNBPositive Net Change
biotechnology biotechs medical pharmaceuticals
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment
by Zacks Equity Research
IceCure Medical shares surge after FDA clears ProSense, marking the first minimally invasive breast cancer treatment for women aged 70 and above.
WSTPositive Net Change MEDPPositive Net Change NVSTNegative Net Change ICCMNo Net Change
medical medical-devices
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
by Sundeep Ganoria
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
AZNNegative Net Change PFEPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up
by Zacks Equity Research
Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.
RDYNegative Net Change ESPRPositive Net Change COLLNegative Net Change AVDLPositive Net Change
medical
4 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run. Stocks like MMS, MD, SBH and STT are seeing price strength, and the momentum is likely to continue.
STTNegative Net Change SBHPositive Net Change MDNegative Net Change MMSNegative Net Change
business-services finance medical retail
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
by Zacks Equity Research
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
CRMDNegative Net Change MRUSNegative Net Change KNSANegative Net Change GMABNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories and Micron Technology
by Zacks Equity Research
AMD, Abbott and Micron showcase strong momentum as AI demand, medical innovation and memory recovery drive growth prospects.
ABTNegative Net Change AMDPositive Net Change MUNegative Net Change
computers finance medical
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns
by Swayta Shah
Broker upgrades fuel optimism for Amicus Therapeutics, Micron and General Dynamics as earnings outlook strengthens.
GDNegative Net Change MUNegative Net Change FOLDPositive Net Change
aerospace computers finance medical tech-stocks
Zacks.com featured highlights include Public Service Enterprise Group, Genpact, The Progressive, Exelon and Butterfly Network
by Zacks Equity Research
Zacks spotlights five top-ranked stocks including Public Service Enterprise Group and Progressive poised to benefit from rising P/E momentum.
EXCNegative Net Change PEGNegative Net Change PGRNegative Net Change GNegative Net Change BFLYPositive Net Change
computers insurance medical utilities
Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk
by Zacks Equity Research
Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.
PFEPositive Net Change NVONegative Net Change MRKNegative Net Change LLYPositive Net Change ABBVNegative Net Change
medical pharmaceuticals